全文获取类型
收费全文 | 40154篇 |
免费 | 3378篇 |
国内免费 | 900篇 |
专业分类
耳鼻咽喉 | 234篇 |
儿科学 | 1252篇 |
妇产科学 | 261篇 |
基础医学 | 5432篇 |
口腔科学 | 109篇 |
临床医学 | 4326篇 |
内科学 | 14255篇 |
皮肤病学 | 198篇 |
神经病学 | 840篇 |
特种医学 | 979篇 |
外国民族医学 | 2篇 |
外科学 | 3539篇 |
综合类 | 4698篇 |
现状与发展 | 6篇 |
一般理论 | 1篇 |
预防医学 | 2369篇 |
眼科学 | 65篇 |
药学 | 2322篇 |
44篇 | |
中国医学 | 433篇 |
肿瘤学 | 3067篇 |
出版年
2024年 | 83篇 |
2023年 | 1372篇 |
2022年 | 2324篇 |
2021年 | 2931篇 |
2020年 | 3123篇 |
2019年 | 1581篇 |
2018年 | 1563篇 |
2017年 | 1523篇 |
2016年 | 1506篇 |
2015年 | 1644篇 |
2014年 | 3436篇 |
2013年 | 2668篇 |
2012年 | 2441篇 |
2011年 | 2480篇 |
2010年 | 2103篇 |
2009年 | 1804篇 |
2008年 | 1408篇 |
2007年 | 1573篇 |
2006年 | 1272篇 |
2005年 | 1023篇 |
2004年 | 877篇 |
2003年 | 808篇 |
2002年 | 754篇 |
2001年 | 662篇 |
2000年 | 510篇 |
1999年 | 481篇 |
1998年 | 287篇 |
1997年 | 209篇 |
1996年 | 272篇 |
1995年 | 193篇 |
1994年 | 168篇 |
1993年 | 125篇 |
1992年 | 222篇 |
1991年 | 179篇 |
1990年 | 159篇 |
1989年 | 156篇 |
1988年 | 161篇 |
1987年 | 97篇 |
1986年 | 61篇 |
1985年 | 38篇 |
1984年 | 31篇 |
1983年 | 10篇 |
1982年 | 12篇 |
1981年 | 17篇 |
1980年 | 13篇 |
1979年 | 10篇 |
1978年 | 7篇 |
1976年 | 8篇 |
1975年 | 11篇 |
1974年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
91.
《Journal of pharmaceutical sciences》2019,108(10):3425-3433
This study aimed at evaluating how encapsulation in a regular nanocarrier (NC) (providing extended circulation time) or in a brain-targeting NC (providing prolonged circulation time and increased brain uptake) may influence the therapeutic index compared with the unformulated drug and to explore the key parameters affecting therapeutic performance using a model-based approach. Pharmacokinetic (PK) models were built with chosen PK parameters. For a scenario where central effect depends on area under the unbound brain concentration curve and peripheral toxicity relates to peak unbound plasma concentration, dose-effect and drug-side effect curves were constructed, and the therapeutic index was evaluated. Regular NC improved the therapeutic index compared with the unformulated drug due to reduced peripheral toxicity, while brain-targeting NC enhanced the therapeutic index by lowering peripheral toxicity and increasing central effect. Decreasing drug release rate or systemic clearance of NC with drug still encapsulated could increase the therapeutic index. Also, a drug with shorter half-life would therapeutically benefit more from a NC encapsulation. This work provides insights into how a NC for brain delivery should be optimized to maximize the therapeutic performance and is helpful to predict if and to what extent a drug with certain PK properties would obtain therapeutic benefit from nanoencapsulation. 相似文献
92.
93.
94.
《Immunobiology》2020,225(2):151891
ObjectiveThe identification of tumor-associated antigens (TAAs) and their corresponding autoantibodies in lung cancer (LC) may expand our vision of cancer immunity. This study aims to screen novel TAAs to distinguish LC from the healthy population.MethodsIn our previous study, 35 genes encoding LC-associated TAAs were identified from the serological analysis of recombinant cDNA expression libraries (SEREX), and Oncomine database was further used to identify potential genes in cancer progression. Autoantibody to TAAs were tested by enzyme-linked immunosorbent assay (ELISA) in sera from 1379 participants in validation set and verification set.FindingsBased on analysis of three independent microarrays in Oncomine, ten genes were consistently dysregulated in LC. The sera level and positive frequency of the anti-TOP2A, anti-ACTR3, anti-RPS6KA5 and anti-PSIP1 from LC patients were higher than normal control in validation set. The area under curve (AUC) of anti-TOP2A, anti-ACTR3, anti-RPS6KA5 and anti-PSIP1 was respectively 0.758, 0.787, 0.707, 0.668. The sensitivity of these four autoantibodies for LC detection ranged from 26.63 % to 32.07 % with the specificity over 90 %. Data from the verification set confirmed the results. Except that, the frequency of serum autoantibody against TOP2A (43.3 %) and ACTR3 (50.0 %) was significantly higher in early stage LC than late stage (23.6 % and 22.3 %, respectively).ConclusionTOP2A, ACTR3, RPS6KA5 and PSIP1 can elicit humoral immune response in LC and their autoantibodies have relationship with the tumorigenesis of LC. Anti-TOP2A and anti-ACTR3 have the potential to serve as a serological biomarkers in early stage LC. 相似文献
95.
《Vaccine》2020,38(51):8185-8193
BackgroundWhile administration of the measles-mumps-rubella (MMR-II®) vaccine has been effective at preventing rubella infection in the United States, the durability of humoral immunity to the rubella component of MMR vaccine has not been widely studied among older adolescents and adults.MethodsIn this longitudinal study, we sought to assess the durability of rubella virus (RV)-specific humoral immunity in a healthy population (n = 98) of adolescents and young adults at two timepoints: ~7 and ~17 years after two doses of MMR-II® vaccination. Levels of circulating antibodies specific to RV were measured by ELISA and an immune-colorimetric neutralization assay. RV-specific memory B cell responses were also measured by ELISpot.ResultsRubella-specific IgG antibody titers, neutralizing antibody titers, and memory B cell responses declined with increasing time since vaccination; however, these decreases were relatively moderate. Memory B cell responses exhibited a greater decline in men compared to women.ConclusionsCollectively, rubella-specific humoral immunity declines following vaccination, although subjects’ antibody titers remain well above the currently recognized threshold for protective immunity. Clinical correlates of protection based on neutralizing antibody titer and memory B cell ELISpot response should be defined. 相似文献
96.
97.
98.
99.
100.
《Journal of cystic fibrosis》2020,19(4):534-539
BackgroundThe combination of lumacaftor and ivacaftor (LUM/IVA) is a recently approved CFTR modulator treatment for homozygous F508del CF patients. Our study aimed at evaluating the change in the rate of lung function decline after one-year treatment with LUM/IVA.MethodsThe study evaluated patients homozygous for F508del, 12 to 23 years old. All had been treated for one year with LUM/IVA. The collected data included the percent predicted values of FEV1 (ppFEV1) and FVC (ppFVC), and the FEV1/FVC ratio (FEV1/FVC), that corresponded to 12, 24, and 36 months prior to, and 12 months after the initiation of LUM/IVA; also, the 3 highest values of the ppFEV1 (and the corresponding ppFVC, and FEV1/FVC) for the periods 0-12 months, 12-24 months, and 24-36 months prior to as well as the 12-month period after the initiation of LUM/IVA. The baseline lung function was estimated before the commencement of the drug. Data were analyzed longitudinally with generalized estimating equations models and continuous linear splines. A single knot was used that corresponded to the time point of LUM/IVA initiation.ResultsFifty-two patients were analyzed. The multivariate longitudinal analysis of spirometric indices with linear splines demonstrated a significant change in the slopes of ppFEV1 and ppFVC decline, reflecting a significant improvement after the initiation of LUM/IVA treatment.ConclusionsIn this real-world study, lung function improved over a relatively short time period of only one year, after the commencement of LUM/IVA. 相似文献